Key to the development of ReveraGen’s lead compound, VBP15, was the recognition that there are sub-properties of glucocorticoids that are associated with either efficacy or side effects.
ReveraGen's expertise in steroid chemistry was used to change the steroid chemistry to optimize for these sub-properties: transactivation (linked to side effects), Learn more >
In the News
January 2015: Action Duchenne announce £55,000 funding for biomarker panel research project
We are delighted to announce that the project titled ‘Definition of pharmacodynamics biomarker panel in a Phase 2a clinical trial of VBP15 in DMD’ has successfully completed our peer-review process. The aim of this proposal is to address the increasing concern that there aren’t enough Learn more >
At ReveraGen, we are committed to improving the lives of neuromuscular disease patients.
We are a drug development company engaged in the discovery and development of proprietary therapeutic products for neuromuscular and inflammatory diseases. We are pursuing small molecule drug development for selected indications. ReveraGen’s lead compound, VBP15, is a novel anti-inflammatory currently in development for the chronic treatment of Duchenne muscular dystrophy (DMD). Additional indications and second-generation product candidates are in the pipeline.